DIAGNOSIS OF ENDOCRINE DISEASE

High-yield thyroid fine-needle aspiration cytology: an update focused on ancillary techniques improving its accuracy

M Bongiovanni, P Trimboli1,2, E D Rossi3, G Fadda3, A Nobile and L Giovanella2

Institute of Pathology, University Hospital, Rue du Bugnon 25, 1011 Lausanne, Switzerland, 1Section of Endocrinology and Diabetology, Ospedale Israelitico, Piazza San Bartolomeo all’Isola 21, 00186 Rome, Italy, 2Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Viale Officina 3, 6500 Bellinzona, Switzerland and 3Division of Anatomic Pathology and Histology, Department of Laboratory Medicine, ‘Agostino Gemelli’ School of Medicine and Hospital, Catholic University, Largo Francesco Vito 1, 00168 Rome, Italy

Correspondence should be addressed to M Bongiovanni
Email: massimo.bongiovanni@chuv.ch

Abstract

Thyroid fine-needle aspiration (FNA) cytology is a fast growing field. One of the most developing areas is represented by molecular tests applied to cytological material. Patients that could benefit the most from these tests are those that have been diagnosed as ‘indeterminate’ on FNA. They could be better stratified in terms of malignancy risk and thus oriented with more confidence to the appropriate management. Taking into consideration the need to improve and keep high the yield of thyroid FNA, professionals from various fields (i.e. molecular biologists, endocrinologists, nuclear medicine physicians and radiologists) are refining and fine-tuning their diagnostic instruments. In particular, all these developments aim at increasing the negative predictive value of FNA to improve the selection of patients for diagnostic surgery. These advances involve terminology, the application of next-generation sequencing to thyroid FNA, the use of immunocyto- and histo-chemistry, the development of new sampling techniques and the increasing use of nuclear medicine as well as molecular imaging in the management of patients with a thyroid nodule. Herein, we review the recent advances in thyroid FNA cytology that could be of interest to the ‘thyroid-care’ community, with particular focus on the indeterminate diagnostic category.

Introduction

Thyroid fine-needle aspiration (FNA) is still among the most commonly performed procedures to evaluate thyroid parenchymal nodules (1). Beside clinically evident and palpable thyroid nodules that are present in up to 7% of the general population, ultrasonographic evaluation of the neck performed in various clinical settings brings to light up to 70% of non-palpable and deep-seated nodules (2, 3, 4). Even if we observe a slight increase in the incidence of thyroid carcinoma, the malignancy rate of thyroid nodules observed in the general population remains low (2–5% among all thyroid nodules). Thus, the detection of these cancers remains a diagnostic challenge (5). Thyroid FNA under ultrasound (US) guidance remains the most accurate and cost-effective method for the initial evaluation of patients with thyroid nodules and has proven its efficacy as a diagnostic test in several diagnostic categories. The sensitivity and specificity of thyroid FNA are reported to be 68–98% and 56–100% respectively. Moreover, thyroid FNA reduces the rate of unnecessary thyroid surgery in patients with benign nodules and allows detection of thyroid cancers requiring a surgical approach (4).
Despite these diagnostic improvements, thyroid FNA still faces some limitations in the detection of follicular carcinoma (FC) and, to a lesser extent, of the follicular variant (FV) of papillary carcinoma (PC), both neoplasms representing the cytological ‘grey zone’ (6). Actually, the malignancy rate of 26% determined after surgery in the follicular neoplasm (FN) diagnostic category contrasts with the excellent results obtained in the other diagnostic categories (7).

New insights emerge from different medical specialties. While the British system for reporting thyroid FNA is under revision, it is now time for the Italian classification to make some adjustments (8). We are moving toward a world-standardized reporting system for thyroid FNA, allowing a more homogenous morphological assessment of the lesions. Following this trend, the performance of traditional single gene and modern multiple genes tests as well as the use of next-generation sequencing (NGS) applied to thyroid FNA can be more precisely compared and evaluated in terms of capability to detect malignancy. Immunocytochemistry (ICC) also seems to have gained a second life, with new antibodies such as GALECTIN3 and HBME1 that are now validated and commonly used in clinical routine. The introduction of antibodies like the VE1 MAB directed against the mutated BRAFV600E gene can be used as a preliminary screening before subsequent use of molecular tests. Finally, the technical evolution of core needle biopsy (CNB) and functional/molecular imaging justifies their use in the non-diagnostic category and the FNs category, respectively, with results that seem promising. The final goal is to reduce the figures of ‘diagnostic’ surgeries by improving the negative predictive value (NPV) of thyroid FNA.

In this review, we provide an up-to-date review of the current practice of thyroid FNA especially dedicated to the daily practice and with particular attention to the ‘indeterminate’ (namely follicular-patterned lesion) diagnostic category.

The new Italian thyroid FNA reporting system and differences between international reporting systems

At the beginning of 2008, the British, Italian and the Bethesda Systems for Reporting Thyroid Cytology (TBSRTC) were created and started to be used in these countries and abroad (8, 9). The use of standardized, consensus-based reporting categories should help make better comparisons between studies and thus allow a more comprehensive management of lesions (10). All the above-mentioned classification systems include the following categories: non-diagnostic, benign, indeterminate/FN, suspicious for malignancy and malignant (Table 1). TBSRTC included an additional category, the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) whose role was to collect those lesions that were difficult to classify in an appropriate diagnostic category due to technical limitations, ambiguous morphological features or paucity of material. The recommendations resulting from the National Cancer Institute Bethesda Conference included for each reporting category, a range of risks of occurrence of a malignant tumor. TBSRTC has achieved its purpose of standardizing the reporting of thyroid cytology in US and some extra US countries, as evidenced by its high overall accuracy (7, 11).

Concerning the European situation, except for UK and Italy, no country has proposed a reporting system so far.

Table 1

<table>
<thead>
<tr>
<th>Italy, 2014</th>
<th>Bethesda, USA, 2008</th>
<th>UK RCPPath, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIR1 non-diagnostic</td>
<td>i) Non-diagnostic or unsatisfactory Cyst fluid only</td>
<td>Thy1/Thy1c Non-diagnostic for cytological diagnosis</td>
</tr>
<tr>
<td>TIR1C non-diagnostic – cystic</td>
<td>ii) Benign</td>
<td>Unsatisfactory, consistent with cyst</td>
</tr>
<tr>
<td>TIR2 non-malignant/benign</td>
<td>iii) Atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS)</td>
<td>Thy2/Thy2c Non-neoplastic</td>
</tr>
<tr>
<td>TIR3A low-risk indeterminate lesion (LRIL)</td>
<td>iv) Follicular neoplasm or suspicious for a FN (FN/AFN)</td>
<td>Thy3a Neoplasm possible – atypia/non-diagnostic</td>
</tr>
<tr>
<td>TIR3B high-risk indeterminate lesion (HRIL)</td>
<td>v) Suspicious of malignancy</td>
<td>Thy3f Neoplasm possible – suggesting FN</td>
</tr>
<tr>
<td>TIR4 suspicious of malignancy</td>
<td>vi) Malignant</td>
<td>Thy4 Suspicious of malignancy</td>
</tr>
<tr>
<td>TIR5 malignant</td>
<td></td>
<td>Thy5 Malignant</td>
</tr>
</tbody>
</table>

www.eje-online.org
Following the publication of TBSRTC, a working group of the Royal College of Pathologists (RCPath) updated the reporting system already in use since 2002 in the UK, using cytologic criteria similar to those used in TBSRTC (https://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/g089guidanceonthereportingofthyroidcytologyfinal.pdf, accessed 7th August 2015). Moreover, this working group decided that it might be of interest to evaluate the interobserver reproducibility of the RCPath system (12). The main difference between the UK RCPath and TBSRTC systems is that the UK RCPath classification assumes that all indeterminate and suspicious for malignancy thyroid nodules will be reviewed in a multidisciplinary clinical team meeting before a clinical decision is made. Conversely, every TBSRTC category has its own estimated risk of malignant occurrence associated with a suggested therapeutic action.

In Italy, the classification proposed in 2007 by the Italian Society for Anatomic Pathology and Cytology (SIAPEC), jointly with the Italian division of the International Academy of Pathology and the two most important societies of endocrinology, the Italian Society of Endocrinology (SIE) and the Endocrinologist Medical Association (AME), was a five-tiered reporting system (13). A recent update has been proposed by the SIAPEC in agreement with the SIE, the AME and the Italian Association of Thyroid (AIT) (Table 2) (8). It is characterized by two important additional features compared with the previous one: i) the subdivision of the non-diagnostic category in non-diagnostic (TIR1) and non-diagnostic cystic (TIR1C) and the division of the thyroid follicular proliferation category (TIR3) into two subgroups: low-risk indeterminate lesion (LRIL) and high-risk indeterminate lesion (HRIL) and ii) the inclusion of an estimated risk of malignancy for each reporting category, analogous with TBSRTC.

The suggested clinical actions have been modified accordingly. For the TIR1 category, the clinical recommendation of the 2007 system was to repeat the aspiration after 1 month in order to collect enough material to achieve a correct diagnosis. In the recent update, the Italian Working Group has included the possibility of sampling lesions repetitively non-diagnostic on FNA by using a CNB. This has been evaluated favourably by Korean and Italian studies (14, 15). For the TIR1C (cystic lesions), a decision is taken by the clinician based on the clinical and ultrasonographic findings. For the TIR2 (non-malignant/benign lesions), the clinical recommendation is to repeat the FNA only if there are significant clinical or ultrasonographic changes in the nodule. Patients with TIR3A – LRIL should benefit from a new aspiration within 6 months following the use of this category. The clinical management of these lesions, especially the decision regarding the surgical consultation, will be defined after the evaluation of the cytological and clinical pictures. The TIR3B – HRIL warrants a surgical resection because of the significantly high risk of malignancy at histology, which cannot be predicted by the evaluation of the cytological material alone. In follicular lesions, the frozen section examination is not recommended. For both TIR3A and TIR3B subgroups, the use of molecular techniques is regarded as an additional helpful parameter, but not sufficient by itself to select those cases that may be addressed to the surgical consultation.

The auspices of all physicians involved in the diagnosis and treatment of thyroid nodules is the creation of a global reporting system for thyroid cytology that includes the strongest parts of each existing classification in order to minimize the risk of unnecessary surgical procedures.

**Table 2** The new Italian classification system with diagnostic categories, expected risk of malignancy, and suggested actions.

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnostic category</th>
<th>Expected risk of malignancy</th>
<th>Suggested actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIR1</td>
<td>Non-diagnostic</td>
<td>Undefined</td>
<td>Repeat US-guided FNA after at least 1 month Evaluate the clinical setting and/or repeat FNA</td>
</tr>
<tr>
<td>TIR1C</td>
<td>Non-diagnostic – cystic</td>
<td>Low (variable on the basis of clinical findings)</td>
<td>Follow-up Repeat FNA/clinical follow-up Surgery</td>
</tr>
<tr>
<td>TIR2</td>
<td>Non malignant</td>
<td>&lt;3%</td>
<td>Surgery</td>
</tr>
<tr>
<td>TIR3A</td>
<td>Low-risk indeterminate lesion (LRIL)</td>
<td>&lt;10%</td>
<td>Surgery</td>
</tr>
<tr>
<td>TIR3B</td>
<td>High-risk indeterminate lesion (HRIL)</td>
<td>15–30%</td>
<td>Surgery</td>
</tr>
<tr>
<td>TIR4</td>
<td>Suspicious of malignancy</td>
<td>60–80%</td>
<td>Surgery</td>
</tr>
<tr>
<td>TIR5</td>
<td>Malignant</td>
<td>&gt;95%</td>
<td>Surgery</td>
</tr>
</tbody>
</table>
markers (16). For this reason, the latest American Thyroid Association (ATA) guidelines recommends incorporating molecular testing in the algorithms used to manage patients with indeterminate thyroid nodules (3). A recent comment of the American Association of Clinical Endocrinologists (AACE)/ATA suggests that molecular testing may be considered in patients with nodules > 1 cm and/or with an indeterminate result on cytology (AUS/FLUS or FN/suspicious for a FN (SFN)) (17). Currently, molecular testing as a diagnostic aid is greatly focused on the indeterminate category.

What are the most useful molecular alterations that can be screened in a routine workup in cases with indeterminate cytology and how to apply them to thyroid FNA? The most promising ones seem to be BRAF gene mutation followed by PAX8/PPARγ translocation. In the presence of such alterations, the positive predictive value (PPV) for cancer is close to 100 and 80% respectively. Others markers are the RET/PTC translocations and the RAS-family mutations, but their PPV for cancer is lower, because these alterations are also detected in a variable percentage of non-malignant lesions. The BRAF mutation assay, due to its sensitivity for PC close to 100% also has a diagnostic value in the suspicious for malignancy category. If found positive in a case diagnosed as suspicious for PC on cytology, a frozen section analysis (usually required in such a case) can be avoided and the patient can be directly referred to the surgeon to perform a total thyroidectomy as well as a selective lymph-node resection in some cases. Moreover, BRAF mutation PPV also warrants its use in the malignant category, even if its effective value as a prognostic marker is still under debate (18). The BRAF point mutations occur in up to 75% of PC cases, but can be lower due to important geographic variability. RET/PTC translocations include numerous variants, the most frequent ones being the RET/PTC1 and RET/PTC3 translocations. Both are found more frequently in patients with a previous history of radiation exposure. RET/PTC1 translocation is more often associated with the FV of PC, while RET/PTC3 translocation is more often associated with the solid variant (19, 20, 21). RET/PTC translocations have also been described in follicular adenoma (FA) and follicular oncocytic carcinoma, and are no more exclusively restricted to PC (22). The PAX8/PPARγ translocation is found in FC with frequencies up to 30%, to a lesser extent in some FV of PC and rarely in FA (23, 24). For some authors, the presence of the PAX8/PPARγ translocation in an FA in which capsular and/or vascular invasion could not be demonstrated histologically warrants the use of the term ‘in situ’ FC, corresponding to a probable FC. Other molecular alterations, i.e. point mutation in the three RAS genes (H, K, and N), have also been implicated in the pathogenesis of thyroid carcinomas, but their specificity is lower than that of the previously mentioned markers, as these mutations have also been identified in quite a high percentage of FA (25). Among these mutations, codon 61 of the NRAS gene is the most frequently mutated site, and seems to be also associated with distant metastases (26, 27).

There are two possibilities for the practicing clinician to run molecular tests on an aspirate: outsourcing the test or using in-house facilities. In the first case, the material collected during the FNA (requires a new sampling of the nodule) is sent to a centralized laboratory for analysis. Currently, the two most well-known companies offering such services are Veracyte, San Francisco, CA, USA (AFIRMA gene classifier test) and Interpace Diagnostics, Pittsburgh, PA, USA (miRInform thyroid test – now ThyGenX) (28, 29). The first one is a rule-out test, in the sense that it tells which cases have a major probability to be benign. It is based on a study of the expression of mRNA from several genes in order to identify cases with a high NPV. The sensitivity, specificity, and NPV for a FN/SFN are 90, 49, and 94% respectively (28). The second test is a rule-in test, in the sense that it tells which cases have a high probability to be malignant (29). It is based on a genetic study of mutations and translocations involving BRAF, RAS, RET/PTC, and PAX8/PPARγ in thyroid FNA in order to identify cases with a high PPV that can be directly addressed to surgery with a more extensive management than simple lobectomy. The sensitivity, specificity and PPV in case of indeterminate or non-diagnostic cytologic diagnosis are 48, 89, and 81% respectively (30). In follicular lesions in which a conservative approach is preferred (either because the patients do not want to be operated on or because the lesion is clinically not suspicious), one should make use of a ‘rule out’ test with high NPV. On the contrary, if surgery is warranted, the positive result of a ‘rule in’ test plays in favor of a surgical treatment. Currently, both tests are only available in the USA. On the other hand, running in-house molecular tests is more cost-effective and less restraining for the cytopathologist. For FNs, only RAS mutations and PAX8/PPARγ rearrangement can be detected. For FNs with atypical nuclei (suspicous for a PC), only BRAF and RAS mutations as well as RET/PTC rearrangement can be detected.

More recently, other possibilities to study FN/SFN thyroid FNA with molecular tests have been proposed, including the ThyraMIR test, by Interpace Diagnostics, a microRNA gene expression classifier that, in association
with the ThyGenX, shows NPV of 94% and PPV of 74%. Another test is the ThyroSeq v2, by CBLPATH and developed by the University of Pittsburgh Medical Center Division of Molecular and Genomic Pathology, which proposes a panel of ~60 molecular markers associated to malignancy analyzed with NGS technology. The reported sensitivity, specificity and NPV and PPV for a FN/SFN are 90, 93, 96, and 83% respectively for this test (31, 32).

If the cytopathologist decides to use in-house available molecular tests, it is noteworthy to know that a large spectrum of cytological preparations/materials can be used. Actually, several authors have demonstrated the feasibility of molecular testing (including NGS) in routine thyroid FNA using air-dried, spray-fixed, ethanol-fixed smears, or even liquid-based cytology (LBC) material preserved in alcoholic fixative solution (33, 34, 35).

The result of the molecular tests can be used as additional information along with clinical, ultrasonographic features and patient’s health condition. From these data, a malignancy risk stratification of patients with an AUS/FLUS and FN/SFN diagnosis can be evaluated to decide whether or not surgery is indicated (36). The gain in sensitivity attributable to the application of molecular tests to FNA material is around 20%, reaching 80% as opposed to 60% with cytological analysis alone (35). We should be aware that the main disadvantage of the application of molecular mutational tests to thyroid FNA remains the fact that 30–40% of thyroid cancers do not harbor known mutations.

**Immunocytochemistry**

In the last few years, European research groups have evidenced the potential aid of the use of ICC on FNA material, showing that it can be an accurate diagnostic and predictive tool. However, it does have a significantly lower specificity than molecular testing, especially in the category of FNs (37, 38, 39, 40). The issues in the application of ICC to cytological smears proved to be solved with the introduction of LBC which has the advantage to standardize pre-analytical conditions. This method is an alternative for collection and preparation of specimens including both cervical and FNA samples (37, 40). Even if there are controversies about the use of LBC in the field of thyroid cytopathology, a proven advantage of this type of processing is its reliability for the use of ancillary techniques (ICC and molecular testing) (34, 40).

Unfortunately, none of the immunomarkers studied so far have demonstrated sufficient diagnostic accuracy to be used alone, a reason why the use of a panel made up of two

**Figure 1**

(A) GALECTIN3 expression in a follicular lesion classified Tir3B on liquid-based cytology (LBC; immunostain, 60×). (B) Membranous expression of HBME1 in a follicular lesion classified Tir3B on LBC (immunostain, 60×). This case turned out to be a papillary thyroid carcinoma, follicular variant, with intense membranous/cytoplasmic expression of HBME1 (inset, immunostain, 60×). (C) VE1 expression in a lesion classified Tir4 (suspicious for carcinoma) on LBC (immunostain, 60×).
or more immunomarkers is recommended, if not necessary. In most cases, it includes GALECTIN3 (Fig. 1A), HBME1 (Fig. 1B), and CYTOKERATIN19 (39, 41, 42). In a recent paper, we selected 120 cases including both cytological and histological materials, and applied a panel only made up of GALECTIN3 and HBME1 (37). Even though Fadda et al. (37) assessed that, in the category of FNs (50 cases) a concordant positive panel was associated with 77% malignant histological outcome, the low specificity of ICC could only suggest but not prove a malignant histology. In the case of a thyroid lesion classified AUS/FLUS and FN/SFN, the study of the expression of GALECTIN3 and HBME1 by the follicular cells may suggest the possibility to distinguish between two subtypes of lesions: low-risk (with both GALECTIN3 and HBME1 negative) and high-risk (both GALECTIN3 and HBME1 positive) with different management and follow-up. However, the low specificity of these immunomarkers cannot guarantee a definitive diagnosis of malignancy (37).

Moreover, a series of promising immunomarkers have been studied in recent years, even if their use in routine is far from being achieved. CD44 has shown a high sensitivity in the detection of PC (97%), although with a relatively poor specificity (43). Ki-67 proliferation index has been studied with somewhat conflicting results based on the value of nuclear expression considered as ‘positive’ (44, 45). Recently, a new interest has been given to the emerging role of a specific monoclonal antibody (VE1) directed against the mutated BRAFV600E protein (Fig. 1C) (46, 47). The scant literature especially in its cytological application (to date only two published series) needs to be empowered by larger and more extensive clinical series. Allegedly, a moderate (2+) or strong (3+) intensity of VE1 expression might be significantly correlated with the molecular BRAFV600E mutational status (46). In a recent paper, we underlined that VE1 antibody represents a feasible first-line approach to evaluate BRAFV600E mutation and might be a valid screening tool to select cases needing a molecular analysis. A statistically proven correlation has been shown between molecular testing and VE1 positivity ($P<0.0001$) in PTC (46). Thus, the use of VE1 marker might add some diagnostic and prognostic value for the management of indeterminate thyroid lesions with a positive GALECTIN3 and HBME1 immunopanel and it may represent the first step for selecting cases which perform molecular detection.

### Core needle biopsy

Despite important diagnostic improvements, a non-negligible rate of thyroid FNA is still considered inadequate (7, 48). These last years, several single-institution articles reported the use of CNB as a second-line approach in these thyroid lesions with prior inadequate or indeterminate cytology (49). Data from these papers are interesting and, more recently, this option was included in thyroid AACE/AME/European Thyroid Association (ETA) guidelines and Italian consensus for thyroid cytology (8, 48).

The major evidence of the value of thyroid CNB has been obtained in lesions considered inadequate (non-diagnostic) on thyroid FNA (50, 51, 52, 53, 54). In this context, a relevant contribution was published by Samir et al. (50). In this study, CNB followed by a second FNA were performed in 90 nodules that had been inadequately sampled one or two times by FNA, and in up to 87% the combination of these two techniques yielded a satisfactory result. Similarly, a study by Zhang et al. (51) used both CNB and FNA in a large series of nodules with inadequate or suboptimal cytological outcome, and the inadequacy rate was reduced from 8.7 to 3.4% thanks to the use of both techniques. Moreover, Na et al. (54) compared CNB to a second FNA in 64 nodules inadequately sampled by a first FNA, and a significant difference was found in the number of inadequate specimens obtained by repeat FNA (28%) vs CNB (1.6%). Therefore, the use of CNB should be strongly considered as an alternative to diagnostic surgery in these patients.

Considering indeterminate diagnosis of FN/SFN, some papers describe the use of CNB (14, 15, 54, 55, 56, 57). In a study by Park et al., CNB applied to cytologically
indeterminate nodules reached a satisfactory diagnosis in all cases, with 77.8% of cases benign, 1.8% still indeterminate and 20.3% malignant. Na et al. evaluated with CNB 161 nodules diagnosed AUS/FLUS and FN/SFN according to TBSRTC, and reached a correct diagnosis in 66.7% of benign and 67.7% of malignant tumors. A paper by Nasrollah et al. reported that a CNB sampling a nodule’s capsule allowed reaching a high diagnostic accuracy, with results corroborated by other studies. Regardless of these data, CNB has not been recommended in nodules with indeterminate diagnosis (follicular lesion) due to low evidence obtained to date (3, 48). Even if uncommon, in case of lesions suspicious of lymphoma and malignancies metastatic to the thyroid, CNB can be very useful.

CNB sample consists of tissue fragments of 1.5 cm in length and with size up to 500 μ (Fig. 2). These specimens constitute an optimal material for morphological examination (micro-biopsy) and extensive ancillary examinations (immunohistochemistry, molecular testing) (58, 59). Overall, 100% concordance has been reported between immunohistochemical evaluation of BRAF expression using the VE1 antibody and mutational analysis performed by pyrosequencing when using the same CNB material (59).

**Functional and molecular imaging**

The natural evolution of nodular thyroid disease includes growth of established nodules, appearance of new nodules, and development of functional autonomy over time (60). Considering a population with continuously increasing life expectancy and the frequent exposure to iodinated radiological contrast media, the risk of iodine-induced hyperthyroidism due to thyroid autonomy should not be neglected (61). Thyroid scintigraphy, with both 99mTc-pertechnetate and 123I reflects the metabolic rate of thyroid cells and is the only test able to demonstrate the presence of autonomously functioning thyroid tissue (Fig. 3A). Thyroid autonomy appears as one (unifocal autonomy) or more (multifocal autonomy) hyperactive area(s) (i.e. hot nodules) while the tracer uptake is variably reduced in normal thyroid-stimulating hormone (TSH)-dependent, thyroid tissue. A timely diagnosis of thyroid autonomy allows early treatment and prevents progression toward obvious hyperthyroidism. Of even higher importance, autonomous nodules are very rarely malignant and current clinical guidelines suggest avoiding evaluating such nodules by FNA (3, 48).

Importantly, although a majority of nonfunctioning ‘cold’ nodules is benign (i.e. 90–95%), almost all thyroid

![Figure 3](image-url)
cancers also appear cold on thyroid scans, explaining the low specificity of cancer detection with this technique. Accordingly, a thyroid scan is usually performed when nodules occur in a background of low-to-normal TSH levels. However, the relationship between thyroid autonomy and TSH levels is dependent on the degree of iodine supply and varies widely from region to region (62). Recent AACE, AME, and ETA guidelines recognize such differences and suggest the use of thyroid scans taking into consideration the iodine supply in different geographical areas. Independent of the iodine supply status and the TSH levels, a thyroid scan with 123I is suggested when evaluating nodules with indeterminate cytological readings (i.e. follicular proliferation) (48).

More recently, new radioactive tracers have become available for thyroid imaging. 99mTc-MIBI uptake within a nodule reflects its abundance of actively functioning mitochondria and therefore its oxidative burden. 99mTc-MIBI scan has been used by several authors to investigate thyroid nodules, in order to differentiate between benign and malignant nodules. This can be assessed either by evaluating the intensity of uptake of 99mTc-MIBI within a nodule and/or by demonstrating an increase in uptake within the nodule over time, in comparison with radiotracer wash-out from normal thyroid tissue (63). A recent meta-analysis, including 21 studies, demonstrated that 99mTc-MIBI scan is a sensitive diagnostic tool to predict malignancy among thyroid nodules in which malignancy is suspected on the basis of conventional diagnostic techniques (64). The pooled sensitivity, on a per lesion-based analysis, was 85% (64). In this setting, low pooled specificity (46%) of 99mTc-MIBI scan is a major concern. However, a higher specificity can be reached when only hypofunctioning ‘cold’ thyroid nodules (as observed with 99mTc-pertechnetate or 123I-iodide scans) are studied with a 99mTc-MIBI scan. Therefore, 99mTc-MIBI should be performed combined with 99mTc-pertechnetate or 123I scan in order to reduce the risk of false positive results with 99mTc-MIBI scan alone (Fig. 3B). It should be emphasized that 99mTc-MIBI scan is not specific enough to differentiate benign and malignant Hürthle cell lesions. In fact, these lesions are both characterized by a significantly increased uptake and/or retention of 99mTc-MIBI, due to their peculiar molecular mechanism of 99mTc-MIBI washout from the cells (63). In summary, due to its low specificity, 99mTc-MIBI scan cannot be recommended as a first-line investigation. As a second-line investigation, it may lead to a lower rate of unnecessary surgeries. Therefore, combined FNA/99mTc-MIBI scan strategies are potentially cost-effective in the management of solitary or dominant thyroid nodules (65). Interestingly, this approach recently proved to be more cost-effective than molecular AFIRMA test (66).

Finally, 18F-FDG, a positron-emitting tracer widely used to study thyroid tumors, has been evaluated to address cytologically inconclusive thyroid nodules (Fig. 3C). A recent meta-analysis regarding the diagnostic performance of 18F-FDG PET or PET/CT in thyroid nodules with indeterminate FNA results reported a pooled sensitivity, specificity, PPV, NPV, and accuracy of 95, 48, 39, 96, and 60% respectively (67). In particular, a negative 18F-FDG scan in patients having a >15 mm thyroid nodule with indeterminate FNA excluded thyroid cancer with a 100% NPV in a pooled population of 225 patients. In contrast, a positive 18F-FDG imaging did not identify thyroid cancer, because ~50% of these patients had benign thyroid nodules. However, negative 18F-FDG PET/CT was able to accurately exclude malignancy in such a challenging clinical scenario and this approach was recently proved to be highly cost-effective (68).

In summary, thyroid scintigraphy with 99mTc-pertechnetate and 123I is of great help to exclude autonomously functioning nodules from FNAC. Additionally, because of their high NPV, 99mTc-MIBI and 18F-FDG can help rule out malignancy and reduce unnecessary surgeries. Their use is now supported by robust clinical data, including meta-analysis, as a second-line procedure to stratify the malignancy risk among thyroid nodules. Overall, this has been suggested to result in a cost-effective management of patients with nodular goiter, particularly when (not so infrequently) cytology is unable to provide a conclusive diagnosis.

**Conclusions**

In conclusion, numerous advances have been developed over the last few years to reduce the inconsistency of thyroid cytology in undetermined lesions, mostly represented by FN/SFN. Any reduction in the percentage of cases that result to be benign at definitive histology is regarded with great interest. Even if there is a low probability to reach a PPV for malignancy by cytology alone as high as in the other diagnostic categories, patients with a FNA diagnosis of FN/SFN will be candidates for additional tests aimed at better evaluating the risk of malignancy. Thus, patients will assume a more evidence-based triage between follow-up and surgery.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding
This review did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


6 Baloch ZW, Fleisher S, LiVolsi VA & Gupta PK. Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. Diagnostic Cytopathology 2002 26 41–44. (doi:10.1002/dc.10045)


48 Na DG, Kim JH, Sung JY, Baek JH, Jung KC, Lee H & Yoo R. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2012 22 468–475. (doi:10.1089/thy.2011.0185)

49 Hahn SY, Shin JH, Han BK, Ko EY & Ko ES. Ultrasonography-guided core needle biopsy for the thyroid nodule: does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results? British Journal of Radiology 2013 86 20130007. (doi:10.1259/bjr.20130007)


51 Choi YJ, Baek JH, Ha EJ, Lim HK, Lee JH, Kim JK, Song DE, Shong YK & Hong SJ. Differences in risk of malignancy and management recommendations in subcategories of thyroid nodules with atypia of undetermined significance or follicular lesion of undetermined


66 Heinzel A, Muller D, Behrendt F, Giovannela L, Motta-Fly FM & Verbarg FA. Thyroid nodules with indeterminate cytology: molecular imaging with (9)(9)mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier. *European Journal of Nuclear Medicine and Molecular Imaging* 2014 **41** 1497–1500. (doi:10.1007/s00259-014-2760-4)
